Co-Diagnostics, Inc. — Form 8-K
Filed November 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Co-Diagnostics submitted a 510(k) premarket notification to the FDA in August 2026 for its Co-Dx PCR Flu A/B RSV test (supported by a clinical study of 1,400+ symptomatic patients across nine U.S. sites) and submitted the CoSara PCR MTB tuberculosis test to India's CDSCO following a clinical performance study of 676 samples (97.3% sensitivity, 96.0% specificity). Q3 2026 revenue was $0.3M versus $0.1M YoY; operating loss was $6.3M versus $7.0M YoY; cash fell from $11.9M (Dec 2025) to $0.7M (Sept 2026); post-quarter the company raised ~$2.1M from J.J. Astor Co. senior secured convertible debt with up to $1.0M additional available.
Why this rating
Regulatory submissions are pathway catalysts for a $10M-market-cap diagnostics company; however, cash depletion to $0.7M and dependence on convertible debt financing signal liquidity stress offsetting optionality value.
Tradability signal
NO TRADE
No trade: price $0.28 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.36 ▲ 34.51% | at our read · unknown $0.27 | +10 min · unknown $0.29 ▲ 8.65% | +30 min · unknown $0.27 ▲ 2.63% | +1 hr · unknown $0.30 ▲ 13.16% | +4 hrs · unknown $0.28 ▲ 6.77% |
The stock had already moved -25.66% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.